This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): NCX 1020
Description: NCX 1020 is a nitric oxide-donating derivative of budesonide, a corticosteroid. The addition of a nitric oxide-donating moiety may lead to smooth muscle relaxation and additional inflammation fighting capabilities.
Deal Structure: In October 2005, NicOx S.A. and Topigen Pharmaceuticals announced that they signed a license and development agreement for NicOx's compound, NCX 1020, in Chronic Obstructive Pulmonary Disease (COPD) and other respiratory disorders. NicOx has granted Topigen rights to NCX 1020 in North America, in return for a 2 million euro upfront payment and up to 52.9 million euros in milestones and commercial success fees, in addition to a share in future revenues.
Under the terms of the agreement, Topigen acquires the development and commercialization rights to NCX 1020 in North America with an option to obtain rights to the rest-of-world from NicOx at a later date. Topigen will manage and fund all further development activities, through to product registration, supervised by a joint management committee and NicOx will receive an undisclosed royalty on Topigen's net sales in North America. Should Topigen exercise the option for rest-of-world rights, NicOx will receive payment of an...See full deal structure in Biomedtracker
Additional information available to subscribers only: